CSPC Pharmaceutical Group Ltd (HKG: 1093), a leading pharmaceutical company based in China, has received approval from the National Medical Products Administration (NMPA) to proceed with a clinical study for its Category 1 chemical drug candidate, SYH2039, which targets advanced malignant tumors.
SYH2039 is a potent inhibitor of methionine adenosine transferase 2A (MAT2A), designed to selectively eliminate tumor cells that are deficient in the methylthioadenosine phosphorylase (MTAP) gene while sparing normal cells. This precision medicine approach has the potential to be used as a monotherapy or in combination with second-generation PRMT5 inhibitors to boost treatment efficacy. Preliminary clinical studies have demonstrated that SYH2039 can effectively suppress the growth of various cancer types with MTAP-deficient tumor cells, including non-small cell lung cancer, glioma, gastroesophageal cancer, pancreatic cancer, and bladder cancer. The drug candidate has shown excellent in vivo and in vitro activity, along with favorable pharmacokinetic properties and safety profiles.
This clinical study marks a significant step forward for CSPC Pharmaceutical Group as they advance SYH2039 towards potential regulatory approval, offering a new treatment option for patients with advanced malignant tumors that are MTAP-deficient.- Flcube.com
